More than 45 organizations, including the AHA, today encouraged members of the Senate Judiciary Committee to support the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974), which the panel is expected to consider next week. The legislation would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. “It is a highly-targeted remedy that will end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs,” the organizations said in a letter to committee leaders. “The Congressional Budget Office has estimated that enacting the CREATES Act would save $3.8 billion over 10 years. We sincerely thank you and your colleagues who have supported the CREATES Act, and we encourage all members of the Committee to vote in favor of the bill.” 

Related News Articles

Headline
The House is expected to begin a final vote Nov. 12 on the Senate-backed funding package, bringing a potential end to the government shutdown one step closer.…
Headline
The Senate Nov. 10 passed legislation to fund the federal government that will now head to the House for a vote as early as the evening of Nov. 12, as an end…
Headline
The Senate Nov. 9 took a critical first step toward ending the government shutdown as seven Democrats and Sen. Angus King, I-Maine, joined Republicans to…
Headline
Senate negotiations on a potential funding deal to end the record-long government shutdown are ongoing, and the chamber is likely to continue working through…
Headline
The AHA expressed support Nov. 3 for the bipartisan Home Health Stabilization Act (H.R. 5142), legislation that would establish a two-year pause on planned…
Headline
There is still no clear end in sight to the government shutdown as today marks day 30 and is approaching the 35-day record that occurred in 2018-2019. Some…